- Home
- UPXI vs THAR Comparison
UPXI vs THAR Comparison
Compare UPXI & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- THAR
- Stock Information
- Founded
- UPXI 2018
- THAR 2017
- Country
- UPXI United States
- THAR United States
- Employees
- UPXI N/A
- THAR N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- THAR Health Care
- Exchange
- UPXI Nasdaq
- THAR Nasdaq
- Market Cap
- UPXI 4.6M
- THAR 4.0M
- IPO Year
- UPXI 2021
- THAR 2022
- Fundamental
- Price
- UPXI $2.92
- THAR $1.90
- Analyst Decision
- UPXI Hold
- THAR Strong Buy
- Analyst Count
- UPXI 1
- THAR 1
- Target Price
- UPXI $25.00
- THAR $17.00
- AVG Volume (30 Days)
- UPXI 71.1K
- THAR 20.9K
- Earning Date
- UPXI 02-14-2025
- THAR 11-07-2024
- Dividend Yield
- UPXI N/A
- THAR N/A
- EPS Growth
- UPXI N/A
- THAR N/A
- EPS
- UPXI N/A
- THAR N/A
- Revenue
- UPXI $18,625,089.00
- THAR N/A
- Revenue This Year
- UPXI $299.03
- THAR N/A
- Revenue Next Year
- UPXI N/A
- THAR N/A
- P/E Ratio
- UPXI N/A
- THAR N/A
- Revenue Growth
- UPXI 4.75
- THAR N/A
- 52 Week Low
- UPXI $2.17
- THAR $1.84
- 52 Week High
- UPXI $15.91
- THAR $7.46
- Technical
- Relative Strength Index (RSI)
- UPXI 34.56
- THAR 43.41
- Support Level
- UPXI $3.35
- THAR $1.86
- Resistance Level
- UPXI $4.50
- THAR $1.95
- Average True Range (ATR)
- UPXI 0.36
- THAR 0.07
- MACD
- UPXI -0.06
- THAR -0.00
- Stochastic Oscillator
- UPXI 5.39
- THAR 16.33
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.